307 related articles for article (PubMed ID: 32325698)
1. MSH6/2 and PD-L1 Expressions Are Associated with Tumor Growth and Invasiveness in Silent Pituitary Adenoma Subtypes.
Uraki S; Ariyasu H; Doi A; Takeshima K; Morita S; Inaba H; Furuta H; Fukuhara N; Inoshita N; Nishioka H; Nakao N; Yamada S; Akamizu T
Int J Mol Sci; 2020 Apr; 21(8):. PubMed ID: 32325698
[TBL] [Abstract][Full Text] [Related]
2. Increased expression of programmed death ligand 1 (PD-L1) in human pituitary tumors.
Mei Y; Bi WL; Greenwald NF; Du Z; Agar NY; Kaiser UB; Woodmansee WW; Reardon DA; Freeman GJ; Fecci PE; Laws ER; Santagata S; Dunn GP; Dunn IF
Oncotarget; 2016 Nov; 7(47):76565-76576. PubMed ID: 27655724
[TBL] [Abstract][Full Text] [Related]
3. Reduced Expression of Mismatch Repair Genes MSH6/MSH2 Directly Promotes Pituitary Tumor Growth via the ATR-Chk1 Pathway.
Uraki S; Ariyasu H; Doi A; Kawai S; Takeshima K; Morita S; Fukai J; Fujita K; Furuta H; Nishi M; Sugano K; Inoshita N; Nakao N; Yamada S; Akamizu T
J Clin Endocrinol Metab; 2018 Mar; 103(3):1171-1179. PubMed ID: 29342268
[TBL] [Abstract][Full Text] [Related]
4. The expression profile of PD-L1 and CD8
Wang PF; Wang TJ; Yang YK; Yao K; Li Z; Li YM; Yan CX
J Neurooncol; 2018 Aug; 139(1):89-95. PubMed ID: 29680903
[TBL] [Abstract][Full Text] [Related]
5. The Progress of Immunotherapy in Refractory Pituitary Adenomas and Pituitary Carcinomas.
Dai C; Liang S; Sun B; Kang J
Front Endocrinol (Lausanne); 2020; 11():608422. PubMed ID: 33362722
[TBL] [Abstract][Full Text] [Related]
6. A Novel Invasive-Related Biomarker in Three Subtypes of Nonfunctioning Pituitary Adenomas.
Chen Y; Chuan HL; Yu SY; Li CZ; Wu ZB; Li GL; Zhang YZ
World Neurosurg; 2017 Apr; 100():514-521. PubMed ID: 28093347
[TBL] [Abstract][Full Text] [Related]
7. Transcriptome Analysis Identifies an Attenuated Local Immune Response in Invasive Nonfunctioning Pituitary Adenomas.
Kim YH; Kim JH
Endocrinol Metab (Seoul); 2019 Sep; 34(3):314-322. PubMed ID: 31565884
[TBL] [Abstract][Full Text] [Related]
8. Identification of a subtype-specific ENC1 gene related to invasiveness in human pituitary null cell adenoma and oncocytomas.
Feng J; Hong L; Wu Y; Li C; Wan H; Li G; Sun Y; Yu S; Chittiboina P; Montgomery B; Zhuang Z; Zhang Y
J Neurooncol; 2014 Sep; 119(2):307-15. PubMed ID: 24916845
[TBL] [Abstract][Full Text] [Related]
9. Somatotropinomas, but not nonfunctioning pituitary adenomas, maintain a functional apoptotic RET/Pit1/ARF/p53 pathway that is blocked by excess GDNF.
Diaz-Rodriguez E; Garcia-Rendueles AR; Ibáñez-Costa A; Gutierrez-Pascual E; Garcia-Lavandeira M; Leal A; Japon MA; Soto A; Venegas E; Tinahones FJ; Garcia-Arnes JA; Benito P; Angeles Galvez M; Jimenez-Reina L; Bernabeu I; Dieguez C; Luque RM; Castaño JP; Alvarez CV
Endocrinology; 2014 Nov; 155(11):4329-40. PubMed ID: 25137025
[TBL] [Abstract][Full Text] [Related]
10. Differential gene expression profiles of invasive and non-invasive non-functioning pituitary adenomas based on microarray analysis.
Galland F; Lacroix L; Saulnier P; Dessen P; Meduri G; Bernier M; Gaillard S; Guibourdenche J; Fournier T; Evain-Brion D; Bidart JM; Chanson P
Endocr Relat Cancer; 2010 Jun; 17(2):361-71. PubMed ID: 20228124
[TBL] [Abstract][Full Text] [Related]
11. Alterations in CD8
Huang X; Xu J; Wu Y; Sheng L; Li Y; Zha B; Sun T; Yang J; Zang S; Liu J
Pathol Oncol Res; 2021; 27():598887. PubMed ID: 34257554
[TBL] [Abstract][Full Text] [Related]
12. Down-regulation of TGF-β RII expression is correlated with tumor growth and invasion in non-functioning pituitary adenomas.
Gu YH; Feng YG
J Clin Neurosci; 2018 Jan; 47():264-268. PubMed ID: 29031543
[TBL] [Abstract][Full Text] [Related]
13. The Complementary Role of Transcription Factors in the Accurate Diagnosis of Clinically Nonfunctioning Pituitary Adenomas.
Nishioka H; Inoshita N; Mete O; Asa SL; Hayashi K; Takeshita A; Fukuhara N; Yamaguchi-Okada M; Takeuchi Y; Yamada S
Endocr Pathol; 2015 Dec; 26(4):349-55. PubMed ID: 26481628
[TBL] [Abstract][Full Text] [Related]
14. Lineage-dependent role of miR-410-3p as oncomiR in gonadotroph and corticotroph pituitary adenomas or tumor suppressor miR in somatotroph adenomas via MAPK, PTEN/AKT, and STAT3 signaling pathways.
Grzywa TM; Klicka K; Rak B; Mehlich D; Garbicz F; Zieliński G; Maksymowicz M; Sajjad E; Włodarski PK
Endocrine; 2019 Sep; 65(3):646-655. PubMed ID: 31165412
[TBL] [Abstract][Full Text] [Related]
15. Nonfunctioning Pituitary Adenoma Recurrence and Its Relationship with Sex, Size, and Hormonal Immunohistochemical Profile.
Batista RL; Trarbach EB; Marques MD; Cescato VA; da Silva GO; Herkenhoff CGB; Cunha-Neto MB; Musolino NR
World Neurosurg; 2018 Dec; 120():e241-e246. PubMed ID: 30138730
[TBL] [Abstract][Full Text] [Related]
16. Analysis of Cyclooxygenase 2, Programmed Cell Death Ligand 1, and Arginase 1 Expression in Human Pituitary Adenoma.
Zhao G; Chen W; He J; Cui C; Zhao L; Zhao Y; Sun C; Nie D; Jin F; Kong L
World Neurosurg; 2020 Dec; 144():e660-e673. PubMed ID: 32920160
[TBL] [Abstract][Full Text] [Related]
17. Differential gene expression of sirtuins between somatotropinomas and nonfunctioning pituitary adenomas.
Grande IPP; Amorim PVGH; Freire ACTB; Jallad RS; Musolino NR; Cescato VA; da Silva GO; Bronstein MD; Trarbach EB
Pituitary; 2018 Aug; 21(4):355-361. PubMed ID: 29564694
[TBL] [Abstract][Full Text] [Related]
18. Silent corticotroph adenomas have unique recurrence characteristics compared with other nonfunctioning pituitary adenomas.
Cho HY; Cho SW; Kim SW; Shin CS; Park KS; Kim SY
Clin Endocrinol (Oxf); 2010 May; 72(5):648-53. PubMed ID: 19650787
[TBL] [Abstract][Full Text] [Related]
19. Aberrant expression of the sFRP and WIF1 genes in invasive non-functioning pituitary adenomas.
Song W; Qian L; Jing G; Jie F; Xiaosong S; Chunhui L; Yangfang L; Guilin L; Gao H; Yazhuo Z
Mol Cell Endocrinol; 2018 Oct; 474():168-175. PubMed ID: 29555596
[TBL] [Abstract][Full Text] [Related]
20. MicroRNAs expression in pituitary tumors: differences related to functional status, pathological features, and clinical behavior.
Vicchio TM; Aliquò F; Ruggeri RM; Ragonese M; Giuffrida G; Cotta OR; Spagnolo F; Torre ML; Alibrandi A; Asmundo A; Angileri FF; Esposito F; Polito F; Oteri R; Aguennouz MH; Cannavò S; Ferraù F
J Endocrinol Invest; 2020 Jul; 43(7):947-958. PubMed ID: 31939196
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
